The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Calutide     N-[4-cyano-3- (trifluoromethyl)phenyl]-3- (4...

Synonyms: Casodex, Cosudex, Kalumid, Raffolutil, bicalutamide, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC722665


Psychiatry related information on NSC722665


High impact information on NSC722665


Chemical compound and disease context of NSC722665


Biological context of NSC722665


Anatomical context of NSC722665


Associations of NSC722665 with other chemical compounds


Gene context of NSC722665


Analytical, diagnostic and therapeutic context of NSC722665

  • PATIENTS AND METHODS: Individual data from 2,161 advanced PCa patients treated in studies comparing bicalutamide to castration were used in a meta-analytic approach to surrogate end-point validation [33].
  • Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia [34].
  • In the groups treated with radiation therapy or radical prostatectomy, regardless of the addition of bicalutamide, the incidence of positive bone scans was low (0.2% to 1.4%) at prostate specific antigen levels less than 5 ng/ml [35].
  • These data suggest that different AR variants are developed and selected for during various types of hormonal treatments, and also, that CAB achieved by orchiectomy and bicalutamide does not act as a selective force for AR amplification [36].
  • Clinical trials are currently in progress to further evaluate bicalutamide as monotherapy in patients with advanced stages of disease and as adjuvant or first-line therapy in patients with early-stage disease [37].


  1. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Bohl, C.E., Gao, W., Miller, D.D., Bell, C.E., Dalton, J.T. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  2. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. Boccardo, F., Rubagotti, A., Battaglia, M., Di Tonno, P., Selvaggi, F.P., Conti, G., Comeri, G., Bertaccini, A., Martorana, G., Galassi, P., Zattoni, F., Macchiarella, A., Siragusa, A., Muscas, G., Durand, F., Potenzoni, D., Manganelli, A., Ferraris, V., Montefiore, F. J. Clin. Oncol. (2005) [Pubmed]
  3. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. Boccardo, F., Rubagotti, A., Barichello, M., Battaglia, M., Carmignani, G., Comeri, G., Conti, G., Cruciani, G., Dammino, S., Delliponti, U., Ditonno, P., Ferraris, V., Lilliu, S., Montefiore, F., Portoghese, F., Spano, G. J. Clin. Oncol. (1999) [Pubmed]
  4. Direct agonist/antagonist functions of dehydroepiandrosterone. Chen, F., Knecht, K., Birzin, E., Fisher, J., Wilkinson, H., Mojena, M., Moreno, C.T., Schmidt, A., Harada, S., Freedman, L.P., Reszka, A.A. Endocrinology (2005) [Pubmed]
  5. Interstitial pneumonitis following bicalutamide treatment for prostate cancer. McCaffrey, J.A., Scher, H.I. J. Urol. (1998) [Pubmed]
  6. Luteinising hormone releasing hormone analogues in the treatment of prostate cancer. Gommersall, L.M., Hayne, D., Shergill, I.S., Arya, M., Wallace, D.M. Expert opinion on pharmacotherapy. (2002) [Pubmed]
  7. Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Chang, H.C., Miyamoto, H., Marwah, P., Lardy, H., Yeh, S., Huang, K.E., Chang, C. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  8. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kamoto, T., Ogawa, O. Cancer Res. (2005) [Pubmed]
  9. Antiandrogen-induced cell death in LNCaP human prostate cancer cells. Lee, E.C., Zhan, P., Schallhom, R., Packman, K., Tenniswood, M. Cell Death Differ. (2003) [Pubmed]
  10. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. Smith, M.R., Goode, M., Zietman, A.L., McGovern, F.J., Lee, H., Finkelstein, J.S. J. Clin. Oncol. (2004) [Pubmed]
  11. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Festuccia, C., Gravina, G.L., Angelucci, A., Millimaggi, D., Muzi, P., Vicentini, C., Bologna, M. Int. J. Cancer (2005) [Pubmed]
  12. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. Di Lorenzo, G., Perdonà, S., De Placido, S., D'Armiento, M., Gallo, A., Damiano, R., Pingitore, D., Gallo, L., De Sio, M., Autorino, R. J. Urol. (2005) [Pubmed]
  13. Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth. Peternac, D., Klima, I., Cecchini, M.G., Studer, U.E., Thalmann, G.N. J. Urol. (2006) [Pubmed]
  14. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., Miyamoto, M. Cancer Res. (2003) [Pubmed]
  15. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Pandini, G., Mineo, R., Frasca, F., Roberts, C.T., Marcelli, M., Vigneri, R., Belfiore, A. Cancer Res. (2005) [Pubmed]
  16. Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. Baron, S., Manin, M., Beaudoin, C., Leotoing, L., Communal, Y., Veyssiere, G., Morel, L. J. Biol. Chem. (2004) [Pubmed]
  17. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Godoy-Tundidor, S., Hobisch, A., Pfeil, K., Bartsch, G., Culig, Z. Clin. Cancer Res. (2002) [Pubmed]
  18. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Swinnen, J.V., Esquenet, M., Goossens, K., Heyns, W., Verhoeven, G. Cancer Res. (1997) [Pubmed]
  19. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. Soloway, M.S., Schellhammer, P.F., Smith, J.A., Chodak, G.W., Vogelzang, N.J., Kennealey, G.T. J. Urol. (1995) [Pubmed]
  20. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Wang, L.G., Liu, X.M., Kreis, W., Budman, D.R. Biochem. Pharmacol. (1998) [Pubmed]
  21. Effects of long-term treatment with the anti-androgen bicalutamide on human testis: an ultrastructural and morphometric study. Morgante, E., Gradini, R., Realacci, M., Sale, P., D'Eramo, G., Perrone, G.A., Cardillo, M.R., Petrangeli, E., Russo, M., Di Silverio, F. Histopathology (2001) [Pubmed]
  22. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Furr, B.J., Tucker, H. Urology (1996) [Pubmed]
  23. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Scher, H.I., Liebertz, C., Kelly, W.K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Shapiro, L., Schwartz, M. J. Clin. Oncol. (1997) [Pubmed]
  24. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Taplin, M.E., Bubley, G.J., Ko, Y.J., Small, E.J., Upton, M., Rajeshkumar, B., Balk, S.P. Cancer Res. (1999) [Pubmed]
  25. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. Bohl, C.E., Miller, D.D., Chen, J., Bell, C.E., Dalton, J.T. J. Biol. Chem. (2005) [Pubmed]
  26. Antiandrogens prevent stable DNA-binding of the androgen receptor. Farla, P., Hersmus, R., Trapman, J., Houtsmuller, A.B. J. Cell. Sci. (2005) [Pubmed]
  27. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Song, L.N., Coghlan, M., Gelmann, E.P. Mol. Endocrinol. (2004) [Pubmed]
  28. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Mizokami, A., Koh, E., Fujita, H., Maeda, Y., Egawa, M., Koshida, K., Honma, S., Keller, E.T., Namiki, M. Cancer Res. (2004) [Pubmed]
  29. Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Zhu, H., Mazor, M., Kawano, Y., Walker, M.M., Leung, H.Y., Armstrong, K., Waxman, J., Kypta, R.M. Cancer Res. (2004) [Pubmed]
  30. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Yuan, X., Li, T., Wang, H., Zhang, T., Barua, M., Borgesi, R.A., Bubley, G.J., Lu, M.L., Balk, S.P. Am. J. Pathol. (2006) [Pubmed]
  31. Bicalutamide: clinical pharmacokinetics and metabolism. Cockshott, I.D. Clinical pharmacokinetics. (2004) [Pubmed]
  32. Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Festuccia, C., Gravina, G.L., Muzi, P., Pomante, R., Ventura, L., Vessella, R.L., Vicentini, C., Bologna, M. Endocr. Relat. Cancer (2007) [Pubmed]
  33. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. Collette, L., Burzykowski, T., Carroll, K.J., Newling, D., Morris, T., Schröder, F.H. J. Clin. Oncol. (2005) [Pubmed]
  34. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Tyrrell, C.J., Payne, H., Tammela, T.L., Bakke, A., Lodding, P., Goedhals, L., Van Erps, P., Boon, T., Van De Beek, C., Andersson, S.O., Morris, T., Carroll, K. Int. J. Radiat. Oncol. Biol. Phys. (2004) [Pubmed]
  35. Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? Warren, K.S., Chodak, G.W., See, W.A., Iverson, P., McLeod, D., Wirth, M., Morris, C., Armstrong, J. J. Urol. (2006) [Pubmed]
  36. Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Haapala, K., Hyytinen, E.R., Roiha, M., Laurila, M., Rantala, I., Helin, H.J., Koivisto, P.A. Lab. Invest. (2001) [Pubmed]
  37. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Kolvenbag, G.J., Blackledge, G.R., Gotting-Smith, K. Prostate (1998) [Pubmed]
WikiGenes - Universities